Sorrento therapeutics antibody

Sorrento therapeutics antibody DEFAULT

Unleashing the therapeutic potential of naïve human antibodies

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) together with its subsidiaries (collectively ‘Sorrento’ or the ‘company’) is a clinical stage and commercial biopharmaceutical company developing new antibody-based oncology, anti-infective, and pain therapeutic drug candidates. Sorrento was founded on the development of passive immunization strategies, an approach that has changed the medical practice over the past two decades by allowing the rapid targeting of pathogenic antigens of exogenous, internal (self-antigens) or tumor origin. The key to developing such therapies is access to the broadest possible repertoire of human antibodies to rapidly screen them for binders to the pathogenic antigens of interest.

Sorrento’s recombinant antibody phage display library, G-MAB, contains the antibody variable domains from nearly 600 donors of different ethnicity and sex, which translates into a total of more than 10 quadrillion (1016) distinct antibody sequences and makes it one of the largest libraries of naïve human antibodies available in the world. These fully human antibody fragments provide the building material to construct fully human antibodies for use in immuno-cellular therapies, antibody–drug conjugates (ADCs), oncolytic viruses and antiviral therapies including those against coronaviruses (Fig. 1).

The company’s lead programs in cancer include CD38-targeting chimeric antigen receptor T cells (CAR T) and dimeric antigen receptor T cells (DAR T) therapies in multiple myeloma, and CD38-targeting ADCs in amyloidosis. Sorrento has also harnessed G-MAB for the rapid development of compounds for the prevention and treatment of coronavirus disease (COVID-19), including a SARS-CoV-2 spike protein-targeting neutralizing antibody (COVI-GUARD), a cocktail of SARS-CoV-2 spike protein-targeting neutralizing antibodies (COVI-SHIELD) and an angiotensin converting enzyme 2 (ACE2) decoy (COVIDTRAP).

“Our wide portfolio of immuno-therapeutic assets is unrivaled in the industry, with each asset individually showing great promise, but when put together, we feel they have the potential to break through the most difficult cancer challenges,” said Henry Ji, CEO of Sorrento. “And faced with the unprecedented global challenge of COVID-19, we at Sorrento are working day and night to harness the potential of the G-MAB library to generate therapeutic and protective antibodies of exceptional potential for saving lives.”

Sorrento is looking to expand its portfolio of life-changing therapies through collaborations with like-minded partners worldwide.

Broad and fully human antibody library

Sorrento has built a deep pipeline of therapeutic, prophylactic and diagnostic binders by harnessing the power of its unique recombinant antibody library, G-MAB. The G-MAB library was built using a proprietary two-step approach to maximize the diversity of naïve donor monoclonal antibodies captured.

First, donor lymphocyte RNAs were amplified using immunoglobulin-specific primers designed to target all five classes of immunoglobulins—IgM, IgG(1–4), IgA, IgD and IgE—and thereby preserve the natural human immunoglobulin diversity. Next, the variable domain regions were selectively and uniformly amplified using a T7 RNA polymerase to create double-stranded cDNAs for insertion into the company’s mammalian cell display vectors. The diversity of the heavy chain component of the cDNA library was estimated to be about 7.1 × 107 and that of the light chain component of the library 2.9 × 108, resulting in a potential combined diversity of about 2.1 × 1016. The high complexity captured by the G-MAB library maximizes the potential to isolate binders with affinities in the single digit nanomolar or even sub-nanomolar range. The ability to identify antibodies with such high affinities directly from the naïve human antibody pool has the added benefit of eliminating the need for in vitro affinity maturation, a rate-limiting step in the antibody development process.

To date, Sorrento has generated human antibodies against many targets important in cancer treatment, including PD-1, PD-L1, CD38, CD123, CD47, VEGFR2, CD137 and also against critical infectious organisms such as SARS-CoV-2, which are at various stages of development.

Antibody collaborations

The core of Sorrento’s technology is provided by its G-MAB recombinant antibody library. This capability is complemented by a full suite of current good manufacturing practice (cGMP)-certified facilities that provide manufacturing, fill/finish and full analytical support capabilities allowing the company to drive drug development from preclinical through investigational new drug (IND) and to late-stage clinical trials.

The facilities include a state-of-the-art cGMP antibody and cell therapy manufacturing unit focused on INDs; a second unit providing aseptic and non-aseptic fill and finish services including lyophilization, labeling/kitting and long-term controlled room temperature, cold and frozen storage; and a viral production unit supporting cell culture, purification, fill and finish processes as well as analytical assay development and quality control testing. In addition to these three California-based units, Sorrento operates an ADC production facility in Suzhou, China, that supports clinical cGMP production of drug linkers as well as antibody conjugation.

These facilities provide Sorrento with a global footprint of capabilities for manufacturing drug substances and drug products for pre-clinical, phase 1 and phase 2 clinical trials, and to deliver life-changing therapies to patients through strong partnerships.

Sours: https://www.nature.com/articles/d43747-020-01112-1

San Diego biotech developing antibody treatments against new COVID strains

San Diego biotech Sorrento Therapeutics announced Tuesday that it is beginning to test antibody treatments that could work against new, faster-spreading strains of the coronavirus.

Those strains have generated considerable concern lately. While the overall number of new coronavirus cases continues to decline across the U.S., some researchers and public health experts say that variants first found in the U.K., South Africa and Brazil could fuel yet another surge.

Sorrento is testing about a dozen antibodies that it believes could work against these strains, as well as others that arise in the future.

“Rather than depending upon a particular vaccine to generate an antibody response that might be protective, we take antibodies that we know are protective and we introduce those,” said Robert Allen, the company’s senior vice president of antiviral and immunotherapy research.

Antibodies are Y-shaped proteins made by the immune system that can latch onto a virus. If they attach tightly enough at the right spot, they can prevent infection.

Teaching the immune system to make the right antibodies is the main goal of current vaccines. Antibodies can serve as COVID-19 treatments by making it harder for the virus to slip into new cells, slowing the progression of the disease.

That’s the approach that Regeneron and Eli Lilly have taken; both companies have antibody therapies authorized by the Food and Drug Administration. But experimental results posted by scientists in late-January showed that Eli Lilly’s antibody wasn’t effective at blocking the South Africa strain of the coronavirus. And while a similar study showed that Regeneron’s two-antibody combination still worked against the South African variant, one of the pair was clearly less effective.

Sorrento believes that at least some of the antibodies it acquired through a partnership with the Mount Sinai Health System in New York won’t be affected by the mutations found in these viral variants. The biotech’s goal is to find two antibodies that can be used together to block a wide swath of strains — either as an intravenous injection or an intranasal spray.

The company is also considering using circular pieces of DNA, known as plasmids, that carry instructions for producing the antibodies. When injected into a person’s arm, these pieces of DNA get absorbed by nearby muscle cells and act like a do-it-yourself guide for them to make the antibodies.

That is all still a ways away, however. So far, the biotech has mostly done early-stage experiments to test how well the antibodies latch onto coronavirus strains and whether they block infection in lab-grown cells, building on initial work from Mount Sinai scientists. Sorrento plans to continue those experiments and could apply for FDA clearance to begin an initial clinical trial by late June.

“Nobody knows as of today if the vaccinations are definitely going to prevent reinfection with different variants,” said Henry Ji, Sorrento’s CEO. “You have to have a means, therapeutically, sitting there ready to go.”

Sours: https://www.sandiegouniontribune.com/business/biotech/story/2021-03-09/san-diego-biotech-developing-antibody-treatments-against-new-covid-strains
  1. Vortech supercharger replacement parts
  2. O2 sensor f150 ecoboost
  3. Writing desk drawers

Sorrento Therapeutics developing antibodies injection and nose drops to fight Covid-19

Companies pursuing the development of similar antibody therapies include Auris Medical, Eli Lilly and Regeneron. The nasal mucosa is the first barrier against continuously inhaled substances, such as allergens and pathogens. 

Scientists at the University of Pennsylvania and biotech firm Regeneron are investigating whether technology developed for gene therapy can be used to make a nasal spray that will prevent infection with the new coronavirus.

Regeneron's antibodies are themselves in clinical testing but have received emergency approval for patients with mild or moderate Covid-19 who are at high-risk of getting severe disease —and were notably used recently to treat President Donald Trump.

Researchers are hoping that the nasal spray could be squirted through the nostrils, enter nasal epithelial cells, and hijack their protein-making machinery so that they make Regeneron's antibodies.

In Europe, researchers from the University of Birmingham, U.K., announced back in November that they had also developed a nasal spray that could potentially protect against the disease.The team from the Healthcare Technologies Institute developed the product using compounds that have already been approved by regulatory authorities in the U.K., Europe and the U.S. This suggests that they are safe for humans.

Sours: https://www.cnbc.com/2020/12/23/sorrento-therapeutics-antibodies-injection-nose-drops-to-fight-covid.html
Sorrento Therapeutics - Benzinga Healthcare Small Cap Conference

Navy teams up with San Diego biotech to deploy COVID-19 tests and treatments

San Diego biotech Sorrento Therapeutics is working with a U.S. Navy research lab to test new coronavirus treatments and tests, according to an announcement from the company on Tuesday.

The deal gives U.S. Naval Medical Research Unit No. 3, a laboratory based in Italy, access to several of Sorrento’s COVID-19 tests and therapies, which the Navy can use to monitor and treat coronavirus cases at field sites and hospitals throughout Liberia, Nigeria, Djibouti, Egypt and Ghana. There’s clear need for such efforts in Africa, with only around 1 percent of the continent’s residents fully vaccinated against the virus, according to the World Health Organization.

It’s all part of the research unit’s mission, which the Navy says is to “study, monitor, and detect emerging and re-emerging disease threats of military and public health importance.” That happens to align with Sorrento’s goal of using antibodies, Y-shaped immune proteins that latch onto specific molecules, to spot and treat various diseases, from cancer to autoimmune disorders to the novel coronavirus.

“We’re both interested in the commercial aspects of this,” said Brian Cooley, Sorrento’s senior vice president of drug delivery.

Cooley says the company’s agreement with the Navy is initially set to last five years, and that the deal doesn’t involve any major payments from either side but is more of a collaboration. The biotech will give the naval lab access to COVI-STIX and COVITRACK, tests that detect proteins from the coronavirus or antibodies made by an immune response to the virus, respectively, information that can tell researchers whether someone is or was previously infected.

Sorrento will also share an experimental antibody it’s developing that latches onto the coronavirus to prevent it from entering cells. The company is testing the treatment as an intravenous infusion and a nasal spray, and it plans to make both versions available to the Navy.

The treatment is already in clinical trials, but Sorrento is hopeful that any additional data the Navy generates could help the biotech secure Food and Drug Administrationapproval for the drug’s use in the U.S. and other countries, too.

Future phases of the partnership will focus on developing tests that can tell whether someone has COVID-19 or another respiratory infection that causes similar symptoms, adds Cooley. And Sorrento says its vast repository of antibodies could allow it to easily come up with antibody-based diagnostics and treatments to other diseases if the Navy wishes to extend the agreement.

It’s not the first time Sorrento has partnered with the Department of Defense. In November, the company was awarded a $34 million contract from the Defense Advanced Research Projects Agency to develop a coronavirus treatment that delivers genetic instructions for making virus-blocking antibodies, which a person’s own cells would then produce. That work is ongoing.

Sours: https://www.sandiegouniontribune.com/business/biotech/story/2021-06-22/navy-teams-up-with-san-diego-biotech-to-deploy-covid-tests-and-treatments

Antibody sorrento therapeutics

News Release

  • COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in this large Phase 2 efficacy trial in the .

  • COVIDROPS™ neutralizing antibody is administered by intranasal instillation.

  • COVIDROPS is highly active against the original SARS-CoV-2 virus, as well as the /Delta and /Alpha variants currently prevalent in the and US.

, (GLOBE NEWSWIRE) -- (Nasdaq: SRNE, "Sorrento") today announced that COVID-19 patients have been dosed in its Phase 2 efficacy trial. Approximately 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms will be enrolled in this large double-blind, randomized clinical trial evaluating COVIDROPS doses of 10 mg or 20 mg against placebo (details can be found on www.ClinicalTrials.gov using the identifier NCT04900428). This study uses a novel decentralized design where subjects are assessed and treated in their homes and received a rapid review and clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the .

A previously completed safety study conducted in the US at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo with all reported adverse effects being mild in severity. The study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the and as well as other territories.

COVIDROPS is administered as a simple intranasal instillation into each nostril to recently infected subjects. The neutralizing antibody drug substance is the same antibody as in COVI-AMG, which is a high potency/low dose IV push injection. The antibody is active in vitro and in animal models of COVID-19 infection against the SARS-CoV-2 variants of concern (VoCs) currently infecting the and the US, including the highly transmissible and virulent /Delta variant, as well as the /Alpha variant and the original SARS-CoV-2 virus. Sorrento is developing a second neutralizing antibody with potential activity against all VoCs, including the Beta () and Gamma (), for entry into the clinic and is intended for use as a cocktail for both intranasal and intravenous administration to augment the coverage of prevailing VoCs. Variants of interest, such as Lambda () and others are constantly evaluated in Sorrento’s active surveillance program.

About

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on .

For more information visit www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to , under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the safety and efficacy of COVIDROPS against SARS-CoV-2, including the original SARS-CoV-2 virus, the /Alpha and the /Delta variants, and any other variants of concern; the expected number of patients and doses in the planned Phase 2 trial in the ; the expected outcome or results of the Phase 2 trials in the and the US; the potential efficacy and safety of COVIDROPS; Sorrento’s plans to apply for Emergency Use Authorization in the US, , , , , or any other territories; Sorrento’s development of a second neutralizing antibody against all variants of concern for use as a cocktail therapy via intranasal or intravenous administration; and the active monitoring of emerging variants of concern, including the Lambda variant. , including Sorrento's Annual Report on Form 10-K for the year ended , and subsequent Quarterly Reports on Form 10-Q filed with the , including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations Contact
, DVM (SVP Corporate Development)
Email: [email protected]

Sorrento® and the Sorrento logo are registered trademarks of

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of

SEMDEXA™ is a trademark of

ZTlido® is a registered trademark owned by

All other trademarks are the property of their respective owners.

©2021 All Rights Reserved.


Primary Logo

Source: Sorrento Therapeutics, Inc.

Sours: https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical
Sorrento Therapeutics CEO Henry Ji on potential coronavirus antibody

Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement for Development of Potent Antibody Combinations Aimed at Neutralizing SARS-CoV-2 and the Emerging United Kingdom and South Africa Variants of COVID-19

  • Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well as current variants of concern.
  • Pre-clinical development of an antibody combination therapeutic including Sorrento and Mount Sinai antibodies for intravenous (IV) and intranasal administration is underway.
  • This step in the fight against COVID-19 follows the progress made with Sorrento’s intravenous STI-2020 (COVI-AMG™) that completed Phase 1 safety studies in healthy volunteers and is now in Phase 2 studies for mild to moderate COVID-19 patients in outpatient and inpatient settings; and Sorrento’s intranasal STI-2099 (COVIDROPS™) that is being tested in Phase 1 studies in healthy volunteers and mild to moderate COVID-19 patients.

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Sorrento and Mount Sinai have entered into an Exclusive License Agreement for a collection of antibodies having SARS-CoV-2 neutralizing properties that were developed by Mount Sinai.

The license also contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized monoclonal antibodies for therapeutic applications.

COVISHIELD, which is under development, will be a combination of two monoclonal antibodies designed to protect against disease caused by existing and emerging variants of SARS-CoV-2. Using the early pandemic variants as well as the emerging variants of concern (“VOCs”) that have increased in prevalence globally through the course of the pandemic, Sorrento identified candidate monoclonal antibody combinations, or “cocktails”, with potent activity against the breadth of these VOCs, including the United Kingdom (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants. Positive results from these laboratory studies are expected to support the future research path and FDA evaluation of COVISHIELD.

COVISHIELD represents a coordination of the discovery and development resources of Sorrento, incorporating intellectual property developed by Mount Sinai, in order to provide a rapid and dynamic means of responding to changes in the public health burden posed by coronaviruses and similar pandemic threat pathogens. Sorrento is developing capabilities and solutions with a goal of contributing to pandemic readiness.

Sorrento Chairman and CEO, Dr. Henry Ji, commented, “We are pleased with the excellent COVISHIELD antibody candidates identified thus far, and we at Sorrento are committed to rapidly developing the COVISHIELD cocktail against known and emerging COVID-19 variants of concern. Sorrento looks forward to future collaborations with the respected research capabilities of Mount Sinai centered on the development of innovative anti-viral and anti-cancer therapeutic candidates.”

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Contact
Alexis Nahama, DVM (SVP Corporate Development)
Email: [email protected]

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2021 Sorrento Therapeutics, Inc. All Rights Reserved.


Sours: https://www.globenewswire.com/news-release/2021/03/09/2189667/0/en/Sorrento-and-Mount-Sinai-Health-System-Enter-Into-Exclusive-License-Agreement-for-Development-of-Potent-Antibody-Combinations-Aimed-at-Neutralizing-SARS-CoV-2-and-the-Emerging-Unit.html

You will also like:

Sorrento Therapeutics Inc

About Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company's multimodal, multipronged approach to fighting cancer is made possible by immuno-oncology platforms, including key assets such as fully human antibodies, clinical-stage immuno-cellular therapies, antibody-drug conjugates, and clinical-stage oncolytic virus. It is also developing potential antiviral therapies and vaccines against coronaviruses, which includes COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC, and COVI-DROPS.

Executive Leadership

Henry H. Ji

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Najjam Asghar

Chief Financial Officer, Senior Vice President

Dorman Followwill

Lead Independent Director

Key Stats

2.00 mean rating - 2 analysts

Revenue (MM, USD)
EPS (USD)

Price To Earnings (TTM)

--

Price To Sales (TTM)

40.85

Price To Book (MRQ)

10.73

Price To Cash Flow (TTM)

--

Total Debt To Equity (MRQ)

60.39

LT Debt To Equity (MRQ)

44.35

Return on Investment (TTM)

-59.01

Return on Equity (TTM)

-49.38
Sours: https://www.reuters.com/companies/SRNE.O


638 639 640 641 642